Medicure (MPH) AI Stock Analysis

• Market Cap: C$10.44M
• Dividend Yield: N/A
• Average Volume (3M): 1.97K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.73
• Revenue Growth: -0.29%
• EPS Growth: -53.83%
• Country: CA
• Employees: 25
• Sector: Healthcare
• Sector Strength: 43
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): N/A
• Shares Outstanding: 10,436,313
• 10 Day Avg. Volume: 728
• 30 Day Avg. Volume: 1,970
• PEG Ratio: -0.17
• Price to Book (P/B): 0.39
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -18.46
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 52 Neutral
• Price Target: C$1.00 ▲( 0.00% Upside)

Medicure's overall stock score reflects significant financial challenges, particularly in profitability and cash flow generation. While the balance sheet is relatively strong, the negative return on equity and declining revenues remain concerns. Recent strategic acquisitions and improvements in certain revenue streams offer potential growth, but the technical indicators and valuation metrics suggest caution. Continued efforts to improve cost management and enhance revenue generation are necessary for a more favorable outlook.

Medicure Business Overview & Revenue Model

Company Description

Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies for the cardiovascular market in Canada and the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company offers ReDS, a non-invasive medical device that offers measurement of lung fluid for the management of congestive heart failure. Further, the company offers Sodium Nitroprusside injection for the reduction of blood pressure for adult and pediatric patients in hypertensive crisis, as well as for producing controlled hypotension to reduce bleeding during surgery, and for the treatment of acute congestive heart failure. It offers products through retail pharmacies, as well as online. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada.

How the Company Makes Money

Medicure makes money through the sale of its pharmaceutical products, which are marketed directly to healthcare providers and institutions. The company's revenue is primarily generated from its flagship cardiovascular drug, which is distributed across various markets. Additionally, Medicure earns income through strategic partnerships and licensing agreements with other pharmaceutical firms, which may involve co-development or co-promotion of products. These collaborations can provide upfront payments, milestone payments, and royalties based on product sales. The company also invests in research and development to expand its product pipeline, aiming to introduce new treatments to the market, thereby increasing its potential revenue streams.

Medicure Financial Statement Overview

Summary

Medicure is experiencing significant profitability challenges with negative EBIT and net income, as well as declining revenues. The balance sheet is a relative strength due to low leverage and a strong equity position, but the negative return on equity and poor cash flow highlight inefficiencies that need addressing.

Income Statement

The income statement indicates challenges with profitability, as evidenced by negative EBIT and net income across the recent periods. Despite a gross profit margin of 56.4% for TTM, the net profit margin is negative at -9.65%. Revenue has also declined by 2.81% compared to the previous year. These factors highlight potential issues in cost management and revenue generation.

Balance Sheet

The balance sheet shows a solid equity position with an equity ratio of 70.14% for TTM, suggesting financial stability. The debt-to-equity ratio is low at 0.046, indicating limited leverage. However, the return on equity is negative at -10.18%, which raises concerns about the company’s ability to generate profit from its equity base.

Cash Flow

Cash flow analysis reveals a concerning picture, with negative free cash flow and operating cash flow in the TTM period. The operating cash flow to net income ratio is negative, aligning with the profitability challenges. There is a significant decline in free cash flow growth rate, suggesting challenges in cash generation.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
21.08M	21.69M	23.07M	21.74M	11.61M	20.17M
	Gross Profit
11.90M	13.99M	16.07M	12.71M	5.13M	12.90M
	EBIT
-3.83M	-854.00K	1.31M	-574.00K	-7.29M	-10.73M
	EBITDA
-1.59M	1.27M	3.44M	2.39M	-4.04M	-17.72M
	Net Income Common Stockholders
-2.03M	-922.00K	1.36M	-727.00K	-6.84M	-19.79M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
71.89M	6.37M	4.86M	3.69M	2.72M	12.96M
	Total Assets
103.76M	28.06M	29.90M	28.41M	34.05M	42.28M
	Total Debt
0.00	544.00K	849.00K	1.17M	1.45M	1.09M
	Net Debt
-24.14M	-5.83M	-4.01M	-2.52M	-1.27M	-11.88M
	Total Liabilities
20.17M	8.16M	8.89M	10.00M	14.91M	15.34M
	Stockholders Equity
83.59M	19.90M	21.00M	18.41M	19.15M	26.94M
Cash Flow		Free Cash Flow
-424.00K	1.81M	1.52M	3.17M	-2.24M	-28.49M
	Operating Cash Flow
-5.00K	2.08M	1.83M	3.99M	-2.24M	-14.64M
	Investing Cash Flow
-419.00K	-270.00K	-310.00K	-2.69M	-7.24M	34.28M
	Financing Cash Flow
-322.00K	-297.00K	-355.00K	-316.00K	-766.00K	-30.26M

Medicure Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:MPH, the sentiment is Positive. The current price of 1 is above the 20-day moving average (MA) of 0.87, above the 50-day MA of 0.84, and above the 200-day MA of 0.91, indicating a bullish trend. The MACD of 0.04 indicates Negative momentum. The RSI at 66.59 is Neutral, neither overbought nor oversold. The STOCH value of 79.54 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:MPH.

Medicure Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	53 Neutral	$5.14B	3.06	-43.57%	2.81%	16.81%	-0.12%
MPH	52 Neutral	C$10.44M	―	-8.79%	―	-0.29%	-53.83%
THTX		$119.81M	―		―	―	―
MDP	71 Outperform	C$83.23M	13.25	11.27%	―	-3.82%	-50.36%
CTX	51 Neutral	C$10.26M	―	-18.52%	―	1.14%	-36.66%
RVV	46 Neutral	C$10.46M	―	-66.49%	―	―	-4.84%
MVMD	35 Underperform	C$8.81M	―	-44.58%	―	-48.33%	47.56%

Medicure Corporate Events

Medicure Inc. Reports 2024 Financial Results with Increased Revenue but Net Loss

Medicure Inc. reported its financial results for the year ended December 31, 2024, with total net revenue of $21.9 million, a slight increase from the previous year. Despite increased revenue from Marley Drug and ZYPITAMAG sales, the company faced a net loss of $1.0 million, primarily due to decreased AGGRASTAT sales and increased costs. The results reflect challenges from pricing competition and increased operational expenses, impacting the company’s profitability.

Medicure to Announce 2024 Financial Results

Medicure Inc. announced it will present its 2024 Year End Financial Results via a conference call on April 29, 2025. The financial results will be filed after market close on April 28, 2025. This announcement is significant for stakeholders as it provides insights into the company’s financial health and operational performance, which could impact its industry positioning and future strategies.

Medicure Expands U.S. Pharmacy Business with West Olympia Acquisition

Medicure Inc. announced the acquisition of West Olympia Pharmacy, expanding its direct-to-consumer pharmacy business in the United States. This acquisition aligns with Medicure’s strategic plan to enhance its pharmacy operations, leveraging West Olympia’s customer base to accelerate the growth of its product ZYPITAMAG and other services. The transaction, valued at USD $975,000, will be funded using existing cash without incurring debt, and is expected to facilitate better access and cost efficiency for patients.

Medicure Completes Strategic Acquisition of Gateway Medical Pharmacy

Medicure Inc. has completed the acquisition of Gateway Medical Pharmacy, located in Portland, Oregon, through its U.S. subsidiary, Medicure Pharma Inc. This strategic move is part of Medicure’s plan to expand its direct-to-consumer pharmacy business, enhancing growth prospects for its products like ZYPITAMAG®. The acquisition did not involve any financing or debt, and no finder fees were paid, indicating a financially prudent transaction. This acquisition positions Medicure to strengthen its market presence and potentially improve service delivery in the healthcare sector.